U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry MIXED
Molecular Formula C22H28NO3.Br
Molecular Weight 434.367
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIPENZOLATE BROMIDE

SMILES

[Br-].CC[N+]1(C)CCCC(C1)OC(=O)C(O)(C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=XEDCWWFPZMHXCM-UHFFFAOYSA-M
InChI=1S/C22H28NO3.BrH/c1-3-23(2)16-10-15-20(17-23)26-21(24)22(25,18-11-6-4-7-12-18)19-13-8-5-9-14-19;/h4-9,11-14,20,25H,3,10,15-17H2,1-2H3;1H/q+1;/p-1

HIDE SMILES / InChI

Molecular Formula C22H27NO3
Molecular Weight 353.4547
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula BrH
Molecular Weight 80.912
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Pipenzolate bromide (JB-323), an anticholinergic agent, which binds to muscarinic acetylcholine receptors as an antagonist. Pipenzolate bromide was studied as an antispasmodic agent, and to treat peptic ulcer.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Palliative
SINSPASMON

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
for dog: orally active antispasmodic agent with an atropine-like action
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
JPX41DUS2B
Record Status Validated (UNII)
Record Version